| Yu, Xinmin |
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies |
|
|
| Completed | 3 | 159 | RoW | SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592 | FibroGen | Chemotherapy Induced Anemia | 04/23 | 04/23 | | |
NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 404 | RoW | PM8002, Paclitaxel, Topotecan | Biotheus Inc. | SCLC | 01/27 | 12/28 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
NCT04691388: A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor |
|
|
| Completed | 2 | 29 | RoW | sintilimab combined with anlotinib | Zhejiang Cancer Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd. | NSCLC | 09/24 | 12/24 | | |
NCT04398940: A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 71 | RoW | TQ-B3139 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 01/22 | 10/22 | | |
NCT05322499: Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer |
|
|
| Not yet recruiting | 2 | 80 | RoW | Camrelizumab, SHR-1210, Irinotecan, Paclitaxel, Paclitaxel-albumin, Docetaxel, Anlotinib | Zhejiang Cancer Hospital | Stage IV Esophagus Squamous Cell Carcinoma | 04/23 | 04/25 | | |
NCT06235983: A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 12 | RoW | LY3537982, Olomorasib | Eli Lilly and Company | Advanced Solid Tumors | 04/26 | 04/27 | | |
NCT05369312: Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients |
|
|
| Not yet recruiting | 1 | 230 | RoW | BPI-442096 | Betta Pharmaceuticals Co., Ltd. | Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer | 05/24 | 05/25 | | |
| Zhang, Xuemei |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
NCT06391502: Vivifrail Program on the Degree of Debilitation in Hospitalized Patients After Venous Hemolysis in Acute Ischemic Stroke |
|
|
| Recruiting | N/A | 2 | RoW | Multi-component Exercise Intervention Program | Affiliated Hospital of Nantong University | Ischemic Stroke, Exercise Therapy, Frailty | 12/24 | 07/25 | | |
